期刊文献+

阿司匹林在心血管疾病中的应用效果 被引量:2

Application of Aspirin in Cardiovascular Diseases
下载PDF
导出
摘要 阿司匹林最初在临床中被用于抗炎和解热止痛,但是随着医疗技术的进步和临床实验的不断加深,发现阿司匹林在心血管疾病的预防工作中能够起到较好的效果。临床中患者服用阿司匹林主要的不良反应为胃肠道刺激症状和出血情况,相关情况的发生率与药物的使用剂量有关,因此在临床中可选用肠溶剂以及胃黏膜保护剂对患者的肠胃进行保护。该药物在临床中的疗效较明确,且价格便宜,使用方便,值得在临床中推广使用,对于治疗临床患者的病症具有积极意义。本文就对其目前在心血管疾病的应用效果进行了归纳分析,希望能够为相关研究人员提供帮助。 Aspirin was initially used in clinic for anti-inflammatory, antipyretic and analgesic purposes, but with the advancement of medical technology and the deepening of clinical trials, it has been found that aspirin can play a better role in the prevention of cardiovascular diseases. The main adverse reactions of patients taking aspirin are gastrointestinal irritation symptoms and bleeding. The incidence of the related conditions is related to the dosage of the drugs. Therefore, intestinal solvents and gastric mucosal protectants can be used to protect the stomach and intestine of patients. It is worth popularizing and using in clinic because of its definite curative effect, low price and convenient use. It has positive significance for treating the disease of clinical patients. This paper summarizes and analyzes its application effect in cardiovascular disease at present, hoping to provide help for relevant researchers.
作者 吴雁 WU Yan(Yulin Traditional Chinese Medicine Hospital,Yulin,Guangxi 53700)
出处 《智慧健康》 2018年第26期62-63,共2页 Smart Healthcare
关键词 阿司匹林 心血管疾病 一级预防 二级预防 Aspirin Cardiovascular disease Primary prevention Two level prevention
  • 相关文献

参考文献9

二级参考文献62

  • 1李小鹰.阿司匹林在动脉硬化性心血管疾病中的临床应用:中国专家共识(2005)[J].中华心血管病杂志,2006,34(3):281-284. 被引量:194
  • 2Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hyper- tension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Greup[J]. lancet, 1998, 351 (9118) :1755 - 1762.
  • 3Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low- dose aspirin in the primary prevention of cardiovascular disease in women[ J]. N Engl J Med, 2005, 352( 13 ) :1293 - 1304.
  • 4Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group[ J]. N Engl J Med, 1989, 321 (3) : 129 - 135.
  • 5Raju NC, Sobieraj-Teague M, Hirsh J, et al. Effect of aspirin on mortality in the primary prevention of cardiovascular disease [ J ]. Am J Med, 2011,24(7):621 -629.
  • 6Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials[J]. Lancet, 2011,377(9) :31 -41.
  • 7Berger JS, Lala A, Krantz M J, et al. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular dis- ease: a recta-analysis of randomized trials [ J]. Am Heart J, 2011, 162(1) :115 - 124,e2.
  • 8Baigent C, Blackwell L, Collins R, et al. Antithrombotic Trialists' (ATF) Collaboration. Aspirin in the primary and secondary preven- tion of vascular disease: collaborative recta-analysis of individual participant data from randomised trials [ J ]. Lancet, 2009, 373 (9678) :1849 - 1860.
  • 9Collins GS, Altman DG. An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study[ J]. BMJ, 2009, 339 :b2584.
  • 10de Ruijter W, Westendorp RG, Assendelft WJ, et al. Use of Fram-ingham risk score and new biomarkers to predict cardiovascular mor- tality in older people: population based observational cohort study [J]. BMJ, 2009, 338:a3083.

共引文献54

同被引文献15

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部